Given the significant need and our innovative research, we are focused on diseases of the central nervous system (CNS).
There is a major need for additional treatments for major depressive disorder.
According to the World Health Organization (WHO), depression is the leading cause of ill health and disability worldwide. According to WHO’s latest estimates, more than 300 million people are now living with depression, an increase of more than 18% between 2005 and 2015. As many as 65 million Americans will experience at least one episode of depression in their lifetime.
Despite multiple drug classes and dozens of approved therapies, additional safe, effective, and well-tolerated options are still needed to successfully treat major depressive disorder (MDD).
Delayed onset of action, side effects and poor tolerability limit effectiveness of many current treatment options.
Challenges with delayed onset of action, side effects and tolerability also limit treatment effectiveness by contributing to non-adherence and/or treatment discontinuation.